[go: up one dir, main page]

ATE467622T1 - Pyrazin-2-carboxamid-derivate als cb2- rezeptormodulatoren - Google Patents

Pyrazin-2-carboxamid-derivate als cb2- rezeptormodulatoren

Info

Publication number
ATE467622T1
ATE467622T1 AT07820497T AT07820497T ATE467622T1 AT E467622 T1 ATE467622 T1 AT E467622T1 AT 07820497 T AT07820497 T AT 07820497T AT 07820497 T AT07820497 T AT 07820497T AT E467622 T1 ATE467622 T1 AT E467622T1
Authority
AT
Austria
Prior art keywords
pyrazine
receptor modulators
carboxamide derivatives
carboxamide
derivatives
Prior art date
Application number
AT07820497T
Other languages
English (en)
Inventor
Michel Dietz
Sabine Gruener
Paul Hebeisen
Reigner Sylvie C Meyer
Matthias Nettekoven
Bernd Puellmann
Stephan Roever
Christoph Ullmer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39166552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE467622(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE467622T1 publication Critical patent/ATE467622T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07820497T 2006-10-04 2007-09-24 Pyrazin-2-carboxamid-derivate als cb2- rezeptormodulatoren ATE467622T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121749 2006-10-04
PCT/EP2007/060090 WO2008040649A2 (en) 2006-10-04 2007-09-24 Pyrazine-2-carboxamide derivatives as cb2 receptor modulators

Publications (1)

Publication Number Publication Date
ATE467622T1 true ATE467622T1 (de) 2010-05-15

Family

ID=39166552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07820497T ATE467622T1 (de) 2006-10-04 2007-09-24 Pyrazin-2-carboxamid-derivate als cb2- rezeptormodulatoren

Country Status (18)

Country Link
US (1) US7691863B2 (de)
EP (1) EP2076499B1 (de)
JP (1) JP5064506B2 (de)
KR (1) KR101114704B1 (de)
CN (1) CN101522644B (de)
AR (1) AR063101A1 (de)
AT (1) ATE467622T1 (de)
AU (1) AU2007304363B2 (de)
BR (1) BRPI0717822A2 (de)
CA (1) CA2664621A1 (de)
CL (1) CL2007002834A1 (de)
DE (1) DE602007006531D1 (de)
ES (1) ES2344128T3 (de)
IL (1) IL197763A0 (de)
MX (1) MX2009003316A (de)
PE (1) PE20080855A1 (de)
TW (1) TW200825065A (de)
WO (1) WO2008040649A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
WO2008040651A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents
US7897621B2 (en) * 2008-03-31 2011-03-01 Hoffmann-La Roche Inc. 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
PE20151073A1 (es) * 2012-12-07 2015-07-25 Hoffmann La Roche Piridina-2-amidas utiles como agonistas de cb2
LT2928882T (lt) * 2012-12-07 2017-03-27 F. Hoffmann-La Roche Ag Pirazino dariniai kaip cb2 receptoriaus agonistai
CN107674061A (zh) * 2012-12-07 2018-02-09 霍夫曼-拉罗奇有限公司 吡啶衍生物
BR112015009600A2 (pt) * 2012-12-07 2017-07-04 Hoffmann La Roche piridina-2-amidas úteis como agonistas cb2
CR20160459A (es) * 2014-04-04 2016-12-02 Eidgenoessische Technische Hochschule Zuerich Nuevos derivados de piridina
KR20210019607A (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
NZ758458A (en) 2017-03-23 2022-07-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
CN109384734B (zh) * 2017-08-14 2023-04-11 上海科胜药物研发有限公司 一种塞尔西帕中间体的制备方法
EP3814328A1 (de) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Neuartige azetidin-substituierte pyridin- und pyrazinverbindungen als inhibitoren des cannabinoid-rezeptors 2
CN116640118B (zh) 2018-06-27 2025-12-19 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
JP7454512B2 (ja) * 2018-06-27 2024-03-22 エフ. ホフマン-ラ ロシュ アーゲー 優先的カンナビノイド2アゴニストとしてのピリジン及びピラジン誘導体
BR112020025013A2 (pt) * 2018-06-27 2021-03-23 F. Hoffmann-La Roche Ag novos compostos de piridina e pirazina como inibidores do receptor 2 de canabinoide
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
WO2023082145A1 (en) * 2021-11-11 2023-05-19 4B Technologies (Suzhou) Limited Intermediate compound of quinoxaline and preparation process thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5738778A (en) * 1980-08-18 1982-03-03 Kyowa Gas Chem Ind Co Ltd Novel cyanopyrazine derivative
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
AU2004221812B2 (en) * 2003-03-19 2010-02-18 Exelixis Inc. Tie-2 modulators and methods of use
EP1641779A1 (de) * 2003-06-18 2006-04-05 AstraZeneca AB 2-substituierte 5, 6-diaryl-pyrazinderivative als cb1 modulator
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
GB0402357D0 (en) 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
MX2007012213A (es) * 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) * 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives

Also Published As

Publication number Publication date
JP2010505788A (ja) 2010-02-25
CL2007002834A1 (es) 2008-05-16
AU2007304363A1 (en) 2008-04-10
PE20080855A1 (es) 2008-06-28
DE602007006531D1 (de) 2010-06-24
US7691863B2 (en) 2010-04-06
WO2008040649A3 (en) 2008-05-29
EP2076499A2 (de) 2009-07-08
KR20090084842A (ko) 2009-08-05
WO2008040649A2 (en) 2008-04-10
AU2007304363B2 (en) 2013-01-17
TW200825065A (en) 2008-06-16
ES2344128T3 (es) 2010-08-18
CN101522644B (zh) 2013-04-24
US20080085905A1 (en) 2008-04-10
CA2664621A1 (en) 2008-04-10
IL197763A0 (en) 2009-12-24
MX2009003316A (es) 2009-04-09
AR063101A1 (es) 2008-12-30
JP5064506B2 (ja) 2012-10-31
EP2076499B1 (de) 2010-05-12
CN101522644A (zh) 2009-09-02
BRPI0717822A2 (pt) 2013-11-12
KR101114704B1 (ko) 2012-03-14

Similar Documents

Publication Publication Date Title
ATE467622T1 (de) Pyrazin-2-carboxamid-derivate als cb2- rezeptormodulatoren
DE602008003116D1 (de) 8-oxychinolinderivate als modulatoren des bradykinin-b2-rezeptors
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
ATE538091T1 (de) Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren
DE602007008222D1 (de) Diazepanderivate als modulatoren von chemokinrezeptoren
DK2014652T3 (da) Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor
ATE413874T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE510831T1 (de) Hydrierte benzoäcüthiophenderivate als immunmodulatoren
BRPI0919172A2 (pt) compostos os quais modulam seletivamente o receptor de cb2
ATE478064T1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
ATE523195T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
EP2009411A4 (de) Kombinations-ausgleichsvorrichtung
DE602006013501D1 (de) Cyclopropylamine als modulatoren des histamin-h3-rezeptors
ATE522517T1 (de) Neue imidazolderivate
BRPI0820779A2 (pt) Derivados de 4-amino-pirimidina
DE502007004371D1 (de) Scharnier-Anordnung
DE602006010508D1 (de) Substituierte triazolderivate als oxytocinantagonisten
FR2924738B1 (fr) Charniere
NO344044B1 (no) Nye triazindionderivater som GABA-B-reseptormodulatorer
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
ATE547407T1 (de) Alkylthiopyrimidine als crth2-antagonisten
ATE492543T1 (de) 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidi - 2-one als cb1-rezeptor-modulatoren
BRPI0822061A2 (pt) Moduladores do receptor canabinoide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2076499

Country of ref document: EP